Is Solventum Corporation Stock Underperforming the Dow?

robot
Abstract generation in progress

Solventum Corporation (SOLV), a healthcare company spun off from 3M in 2024, has been significantly underperforming the Dow Jones Industrial Average. The company’s stock has declined nearly 25.4% from its 52-week high, and its recent Q4 fiscal 2025 earnings showed a revenue beat but a significant earnings miss. Despite these struggles, Wall Street analysts maintain a “Moderate Buy” rating with a considerable upside potential of 42.1%.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin